Hydrotherapy in MPSII
Research type
Research Study
Full title
Does hydrotherapy alleviate pain and improve functional mobility in patients with Mucopolysaccharidosis type II (Hunter syndrome)?
IRAS ID
317767
Contact name
Karolina Stepien
Contact email
Sponsor organisation
Northern Care Alliance NHS Foundation Trust
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
Mucopolysaccharidoses (MPS) are a heterogenous group of conditions with slow progression of symptoms from childhood to adulthood. Clinical manifestations include neurocognitive dysfunction, cardiopulmonary abnormalities, hepatosplenomegaly, skeletal abnormalities, joint pain and swelling.
The pain syndromes seen in patients with all MPS types are complex and often multifactorial with elements of neuropathic pain, musculoskeletal pain and frequently a mixed picture with both.
Non-surgical approaches such as physiotherapy have been advocated as benefitting patients with MPS II. It has shown to decrease joint stiffness, reduce pain and improve strength as documented in some care reports. However, there is limited high quality evidence currently to support its use as a routine part of care for this group of patients.
The aim of this study is to assess the effectiveness of hydrotherapy in the management of joint pain, improved mobility and quality of life in our patients with MPS type II (Hunter syndrome) only.REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
23/NW/0169
Date of REC Opinion
15 Jun 2023
REC opinion
Favourable Opinion